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 Diabetic retinopathy is the most common cause of vision loss among people with 
diabetes and the leading cause of vision impairment and blindness among adults. The 
human retina is known to have a unique lipid profile enriched in very-long-chain 
polyunsaturated fatty acids (VLC-PUFAs) which appear to promote normal retinal 
structure and functions. Significantly decreased levels of VLC-PUFAs and low n-3/n-6 
ratios have been found in the retina of patients with age-related macular degeneration 
(AMD); however, the effects of diabetes on retinal VLC-PUFAs are not clearly 
understood. In this study, we studied the differences in retinal lipid compositions in 
diabetic eyes as compared to age-matched controls in human and animal models. The 
VLC-PUFA levels and n-3/n-6 ratios were unchanged in postmortem diabetic retinas in 
comparison to age-matched control retinas, in part due to the limited number of human 
donor eyes available for this project. To further study the effect of omega-3 
supplementations on VLC-PUFA levels in diabetic models, we chose diabetic Nile rat 
(spontaneous diabetes) and Akita mouse (genetic diabetes) models. After a month of 
supplementation with omega-3 PUFAs, VLC-PUFA levels and n-3/n-6 VLC-PUFA ratios 
increased in diabetic Nile rats in comparison to age-matched control rats. Our results in 
the present study indicate that VLC-PUFA levels are lower in diabetes and diabetic 
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 Diabetes mellitus (DM), a growing public health concern, has reportedly affected 
nearly 422 million people around the world in 2014 (1). Diabetic retinopathy is a major 
complication of diabetes and the leading cause of blindness in 30-60-year-olds. Diabetic 
retinopathy results from chronic diabetic damage to tiny blood vessels in the retina 
caused by high blood sugar (2). Diabetic retinopathy has two phases: an early 
proliferative phase characterized by increased vascular permeability and hemorrhages 
and a late proliferative phase characterized by retinal neovascularization, which is 
accompanied by vision loss (3).  
 The role of lipids in the progression of diabetic retinopathy began to be 
documented in the 1950s. Later studies involving diabetes control and complication trials 
also confirmed that dyslipidemia (altered serum lipid levels) is associated with the 
progression of diabetes (4). Dyslipidemia is a complex disorder involving abnormal 
levels of lipids and altered fatty acid compositions in the plasma that arise due to 
metabolic disproportion partly caused by the imbalance of insulin levels. Although a few 
studies have shown a correlation between dyslipidemia and diabetes, the association is 
not well understood. Both systemic and retina-specific fatty acid profiles are affected by 
diabetes and have been suggested to contribute to the progression of diabetic 
retinopathy. Hence, there is a need to study the alterations of the fatty acid compositions 
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in both retina and serum to understand the disease process and to facilitate 
development of effective therapeutics.  
 Among the fatty acids, long-chain-polyunsaturated fatty acids (LC-PUFAs) have 
been gaining the interest of researchers and supplement companies with regard to 
inflammation and human health. Omega-3 (n-3) LC-PUFAs (eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA)) are anti-inflammatory and omega-6 (n-6) LC-
PUFAs such as arachidonic acid (AA) are proinflammatory in nature. The balance 
between these two fatty acids plays a pivotal role in disease progression and health.  
Mouse model studies, human clinical trials, and epidemiological studies have 
demonstrated that the intake of n-3 LC-PUFAs such as DHA, EPA, or fish (a major 
source of both DHA and EPA) has a protective effect against the progression of many 
lifestyle-related retinal diseases like age-related macular degeneration (AMD), diabetic 
retinopathy, and glaucoma (2, 5, 6)  
 Very-long-chain polyunsaturated fatty acids (VLC-PUFAs) are a recently 
recognized new class of fatty acids that are considered very important for retinal 
membrane fluidity and maintenance of the highly curved membrane disks of the 




Figure 1.1 VLC-PUFA structures 
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 VLC-PUFAs are nondietary fatty acids with chain length greater than 24 carbons 
which have been identified in the vertebrate retina and only a few other tissues such as 
testes. Until recently, very little attention had been paid to these rare C26-C38 retinal 
lipids due to their low abundance (<2% of all retinal fatty acids) and technical difficulties 
in measuring their retinal levels by standard gas chromatography (GC) methods. These 
lipids exhibit a unique hybrid structure, combining a proximal end with a typical saturated 
fatty acid character and a distal end more characteristic of common PUFAs. These rare 
fatty acids cannot be synthesized de novo in vertebrates and are rarely consumed in 
normal diets. They are synthesized in vivo from specific precursors such as α-linolenic 
acid (ALA), EPA (20:5 n-3), linoleic acid (18:2 n-6), and AA (20:4 n-6) through the action 
of an enzyme known as ELOVL4 (Figure 1.2). 
 In a recently published study from our laboratory, we observed that diet can 
profoundly influence retinal lipid (VLC-PUFA) composition.  For example, an outlier 
subject who consumed 7g of fish oil/day showed a six-fold increase in EPA/AA ratio, n-
3/n-6 LC-PUFA ratios in serum, and a subsequent increase in n-3/n-6 VLC-PUFA ratio in 
retina, indicating a strong impact of diet on n-3/n-6 VLC-PUFA ratios in retina. Significant 
correlations were observed between serum n-3/n-6 LC-PUFAs (r=0.91, p<0.001) and n-
3/ n-6 VLC-PUFA ratios (7). Moreover, significant reductions in retinal VLC-PUFA levels 
and n-3/ n-6 ratios were noted in AMD donor eyes relative to age-matched controls.  
With this background, we next decided to explore if retinal VLC-PUFA levels and their n-
3/n-6 ratios were also altered in diabetes and diabetic retinopathy. We hypothesize that 
diabetes and diabetic retinopathy affect the retinal lipid profile in the eyes and that these 
alterations can be ameliorated by dietary supplementation or an n-3 fatty acids rich diet. 
For this investigation, we chose human donor eyes to study the differences in retinal lipid 
profiles along with respective serum, as well as animal models (spontaneous diabetes 






Figure 1.2. Pathways of VLC-PUFA synthesis via ELOVL4 
 
 
LC-PUFA, VLC-PUFA levels and their n-3/n-6 ratios, glucose levels, serum adiponectin, 
and gene expression levels of AdipoR1, a regulatory switch for DHA  (8) and ELOVL4, 
an elongase required for the biosynthesis of very long-chain polyunsaturated fatty acids 
(9).   
 








































































 All chemical reagents, such as methanol, hydrochloric acid, isopropanol, n-
hexane, and diethyl ether, were of gas chromatography mass spectrometry (GC-MS) 
grade and purchased from Fisher Scientific (Pittsburgh, PA, USA). All standards 
including the internal standards such as tridecanoic acid (13:0) and Supelco-37 (a 
commercial mixture of fatty acid methyl esters (FAMEs)) were purchased from Matreya 
(Pleasant Gap, PA, USA). The internal standard, tridecanoic acid, was dissolved in 
nonane at a concentration of 1.0 mg/ml. Fish oil for supplementation was purchased 
from Nordic Naturals, Inc. (Watsonville,CA, USA). EPA (98%) and DHA (98%) were 
purchased from Avanti Chemicals (Alabaster, AL, USA). A Mini BeadBeater-16 and the 
associated mixing beads were purchased from BioSpec Products (Bartlesville, OK, 
USA). Silica gel, glass-encased solid phase extraction (SPE) cartridges (500 mg/6 ml) 
were purchased from Sorbent Technology (Atlanta, GA, USA). A glucometer was 
purchased from Bayer HealthCare LLC (Pittsburgh, PA, USA). Serum adiponectin levels 
were measured by Mouse Adiponectin/Acrp30 Immunoassay (R&D Systems, 







2.2 Sample Collection 
2.2.1 Human Donor Eye Samples 
 All human donor eyes were collected from the Utah Lions Eye Bank. Donor eyes 
with large drusen, severe macular atrophy, macular hemorrhage, or any grossly visible 
chorio-retinal pathologic abnormalities were excluded. Six mm punches of peripheral 
retina and serum samples were collected. All punched human retinal tissues were stored 
in tubes and kept at -80°C. We collected diabetic human donor eyes (n=7) between the 
ages of 76-90. As controls, age-matched control-eyes (n=22) and serum were collected 
using the same procedures. 
 
2.2.2 Nile Rat Model 
 The Nile rat (Arvicanthis niloticus) develops type 2 diabetes in a similar 
progression to humans. In general, Nile rats were fed on guinea pig diet in a special 
room set up with 37°C temperature and 70% humidity. Male Nile rats are a good model 
for spontaneous diabetes because male Nile rats fed Prolab RMH 2000 diet with low 
fiber and high fat for 2 months develop hyperinsulinemia and hyperglycemia leading to 
diet-induced type 2 diabetes. After confirmation of diabetes by blood glucose level 
estimation, all diabetic rats were divided into two groups and fed RMH 2000 to the 
control group (n=4) and RMH 2000 + 3 % fish oil (1560 mg of n-3 fatty acids/5ml) to the 
experimental group (n=4). After 4 weeks of supplementation, all rats were sacrificed, and 
serum, eyes, and other organs were collected. Eyes were dissected under a light 
microscope to separate retinal pigment epithelium (RPE) from retinas, and collected 






2.2.3 Akita Mouse Model 
 Akita mice (C57BL/6J) have the Ins2 mutation which resulted in a single amino 
acid substitution in the insulin 2 gene which causes misfolding of insulin protein. Akita 
mice develop diabetic symptoms, such as hyperglycemia, polydipsia, and polyuria, soon 
after weaning. Four-week-old Akita mice start to display progressive loss of ß cell 
function, ß cell mass reduction, and overt hyperglycemia. For our supplementation 
experiments, we had a very small number of control mice (n=2) and experimental (n=4) 
mice. Three-month-old Akita mice were fed with EPA + DHA (3% of the diet) for 4 
weeks. After supplementation, all mice were sacrificed, organs were harvested, and 
retinas were separated from RPE and used for LC-PUFA and VLC-PUFA analysis. 
Mice were genotyped by PCR amplification of genomic DNA from tail biopsy by 
specific primer pairs for C57BL/6-Ins2Akita/J (fwd: 5’-TGC TGA TGC CCT GGC CTG CT-
3’ ; rev: 5’- TGG TCC CAC ATA TGC ACA TG-3’) 
 
2.3 Extraction of Lipids and Analysis 
 Retina samples were homogenized with a Biospec Beadbeater. The samples 
(100 μl) and internal standards (50 μg of tridecanoic acid) were added in 12 ml glass 
tubes with 4 ml hexane-isopropanol (3:2 v:v) and sonicated for 5 min in an ice water 
bath. After centrifugation at 3,000 rpm for 5 min, the extracted solution supernatant was 
transferred to a clean vial and then dried under a stream of nitrogen. The dried film was 
dissolved in 200 μl hexane, and 2 ml of 4% HCl in methanol was added. The tubes were 
flushed with argon and incubated at 80°C for 4 hr to form fatty acid methyl esters 
(FAMEs) and then allowed to cool. The FAME mixture was extracted three times with 1 
ml distilled water and 2 ml hexane. The hexane layers were combined and dried under 
nitrogen gas. Silica gel, glass-encased SPE cartridges were subsequently used to clean 
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the FAMEs extracts. The cartridge was activated with 6 ml of hexane before loading 
samples. The crude FAMEs extract was dissolved in 200 µl of hexane and loaded onto 
the activated cartridge. The cartridge was washed with 6 ml hexane, and the eluate was 
discarded. Then, the FAMEs were eluted with 5 ml hexane:ether (8:2), and the eluate 
was evaporated under nitrogen gas. The dry film was dissolved in 180 µl of hexane and 
centrifuged for 3 min at 14,000 rpm to remove particles prior to GC-MS analysis. For LC-
PUFAs analysis, 1 µl of sample was injected into the GC-MS instrument. For VLC-
PUFAs analysis, the sample was dried with nitrogen again and re-dissolved in 20 μl of 
nonane, and 5 µl samples were injected into the GC-MS instrument. 
 The Thermo Trace GC-DSQ II system (Thermo Fisher Scientific, Waltham, MA, 
USA) consists of an automatic sample injector (AS 3000), gas chromatograph (GC), 
single quadrupole mass detector, and an analytical workstation. The chromatographic 
separation was carried out with a Rxi-5MS coated 5% diphenyl/95% dimethyl 
polysiloxane capillary column (30 m × 0.25 mm i.d, 0.25 µm film thickness) (Restek, 
Bellefonte, PA, USA). 
 For LC-FA analyses, we used the following mass spectrometry conditions 
(Method A): 1 µl from a 200 µl sample was injected into the GC-MS using a splitless 
mode; the septum purge was on; the injector temperature was set at 200°C. The column 
temperature was programmed as follows: initial temperature 60°C; 5 degree/min to 
170°C; 1 degree/min to 180°C; 2 degree/min to 240°C; 4 degree/min to 290°C; and a 
hold at 290°C for 5 min. Transfer line temperature was 290°C. Helium was used as the 
carrier gas at a flow rate of 1.0 ml/min. Mass spectrometry conditions were as follows: 
electron ionization (EI) mode with full scan (FS) and selected ion monitoring (SIM, m/z 
79, 108, and 150) because m/z 79, 108, and 150 are typical ions of VLC-PUFAs, and n-
3 and n-6 PUFAs can be identified by comparing the ratio of the m/z 108 and 150 ions; 
ion source temperature, 200°C; multiplier voltage, 1182 V; detector delay, 10 min. For 
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peak identification, the data were obtained by collecting the full-scan mass spectra within 
the scan range of 50-650 amu, and these peaks were identified by comparing their mass 
spectra with those in the standard solution and the National Institute of Standards and 
Technology (NIST) library. For the quantification of LC-FAs, the data were obtained by 
FS. Authentic reference compounds were used to calculate the mol percentage of every 
peak. 
 For VLC-PUFAs analyses (Method B), the identification method was described in 
our previous paper (10). We extracted mixed VLC-PUFAs from bovine retina as the 
VLC-PUFA standards to establish retention times because commercial standards are 
not available, and identification of each VLC-PUFA in retinal samples was achieved as 
described by Liu et al (10). For the quantification of VLC-PUFAs, we used similar mass 
spectrometry conditions to the LC-FAs method but with a larger injection volume of 5 µl 
from a 20 µl sample which had been concentrated from a 200 µl original volume. The 
column temperature program was similar to the LC-FAs method but held at 290°C for 35 
min. Mass spectrometry conditions were similar to the LC-FAs method, but the detector 
delay time was 22 min. 
 The low amounts of VLC-PUFAs that are present in the mammalian retina elute 
very late from the GC-MS, and standards are not available commercially which means 
that their quantitation can be particularly challenging. We found that we had to perform 
two separate GC-MS runs linked by common C24 VLC-PUFAs. With Method A, the 
complete set of LC-FAs up to 22 carbons in length and two C24 FAs (24:1n-9 and 24:0) 
can be quantified under full scan mode, and when the chromatogram is re-analyzed 
under SIM mode (m/z 79, 108, and 150), we can identify and quantify all n-3 and n-6 LC-
PUFAs, and even the C24 VLC-PUFAs become detectable and can be quantified by 
comparing their mol percentages relative to the C22 LC-PUFAs. The C24 VLC-PUFAs 
can then be used as the common link between Method A and Method B because they 
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are present in both GC-MS chromatograms. All of the VLC-PUFAs measured by Method 
B can be subsequently quantified relative to the total LC-FAs determined by Method A 
after correcting for the effects of carbon-chain length and the degree of unsaturation on 
the response of the mass spectrometer.  
 
2.4 Genotyping 
 The TaqMan platform (Applied Biosystems, Grand Island, NY, USA) was used 
for genotyping. 7900HT and SDS 2.4 software were used to run the amplification and 
genotype data. The SNPs, rs381253, and rs10753929, used in this study have been 
selected based upon their association with ELOVL4 and AdipoR1 as reported in the 
earlier literature (11, 12). 
 
2.5 Statistical Analysis 
 Variables were expressed using mean and the SEMs, and the differences were 
compared by independent t tests. Statistical analyses were performed using Microsoft 
Excel Software (2016, Microsoft, Redmond, WA). All data are presented as mean ± 











3.1 Effect of Diabetes on Retinal Lipid Profiles in Human Eyes 
 Seven diabetic subject samples were collected (age between 76-90), and their 
serum and retinal punches were analyzed by GC-MS. The retinal VLC-PUFA levels and 
n-3/n-6 VLC-PUFA ratios in human age-matched control versus diabetic retinal punches 
are shown in Figure 3.1. VLC-PUFA levels and n-3/n-6 VLC-PUFA ratios were 
unchanged in diabetic retinas in comparison to age-matched control retinas. The lack of 




Figure 3.1. VLC-PUFA levels in human retinal punches (■ Control 




































We compared the serum lipid profiles of diabetics and age-matched controls 
(Figure 3.2). When we compared systemic biomarkers like EPA/AA, DHA/AA, and n-3/n-
6 LC-PUFA ratios, no differences were observed in diabetic serum when compared to 
age-matched control serum. We next focused on the major VLC-PUFA precursors of 
retinal VLC-PUFAs as follows: 18:3n-3, 18:4n-3, 20:4n-3, 20:5n-3, and 22:5n-3 for n-3 
VLC-PUFAs 18:3n-6, 20:3n-6, 20:4n-6, and 22:4n-6 for n-6 VLC-PUFAs, and the n-3/n-6 
VLC-PUFA precursors in diabetic serum samples were significantly lower in comparison 




Figure 3.2. Comparison of serum lipid biomarkers in diabetes 
subjects with age-matched control subjects (■ Control retina; ■ 



















DNA was available for these subjects studied, so we examined whether variants 
in ELOVL4 and AdipoR1 have any influence on diabetic retinopathy or lipid profiles, but 
we found no significant relationships, nor did we find any statistically significant 
influences for diabetic retinopathy (all P values for comparisons were >0.05). Among the 
seven diabetes subjects, we had three patients with diabetic retinopathy. Therefore, we 
compared diabetic retinopathy subject data with non-retinopathy diabetes subjects as 
shown in Figure 3.3. We found there is no significance in retinal VLC-PUFA levels and 
n3/n6 VLC-PUFA ratios in retinopathy subjects in comparison to non-retinopathy 
diabetes subjects (Figure 3.3). 
 
3.2 Effects of Fish Oil Supplementation on Diabetic Nile Rats 
Due to limited availability of donor diabetic eyes, we chose to investigate the role 




Figure 3.3. Comparison of retinal VLC-PUFAs in diabetes subjects 
with age-matched control subjects (■ Control retina; ■ Diabetic 







































Nile rats (also known as Nile grass rats) because they are diurnal animals with cone-rich 
retinas, and they are a validated model of spontaneous diabetes which in many ways 
mimics humans better than Streptozotocin(STZ)-induced mouse or rat models of 
diabetes. As mentioned in the methods section, we supplemented the group of diabetic 
male Nile rats with 3% fish oil mixed in diet and the other group without fish oil. We 
observed that fish oil supplementation improves retinal n-3/n-6 VLC-PUFA ratios (Figure 
3.4). 
 Figure 3.5 shows the serum lipid profiles in diabetes Nile rats after 
supplementation. After 4 weeks of feeding, the fish oil supplemented group (n=4) had 
significantly higher EPA/AA ratios and VLC-PUFA precursor ratios than the control 




Figure 3.4. Comparison of retinal VLC-PUFA levels in fish oil 
supplemented diabetic Nile rats group with normal diet diabetic Nile 



































Figure 3.5 Comparison of serum lipid biomarkers in fish oil 
supplemented Nile rats with normal diet group (■ Diabetic-ND; ■ 
Diabetic-Fish oil supplement) (P values: *P<0.05; ***P<0.001) 
 
 
 In the retina, the fish oil supplemented group had remarkably higher EPA/AA and 
in comparison with the diabetic control group (p=0.005) (Figure 3.6). Thus, dietary fish oil 
supplementation improved serum VLC-PUFA precursor levels and retinal n-3/n-6 VLC-
PUFA ratios, indicating diet could play a significant role in improving dyslipidemia. We 
also tested the glucose levels of Nile rats and found that serum glucose levels of the fish 
oil supplemented group were significantly reduced in comparison to the control group, 
consistent with beneficial systemic effects of fish oil on diabetes (Figure 3.7).  
 
3.3 Effect of Diabetes on Retinal Lipid Profiles in Akita Mice  
  To study the effects of omega-3 fatty acids on diabetic retinopathy in another 
animal model of diabetic retinopathy, we used Akita mice. We used pure EPA (98%) and 
DHA (98%) to explore the effects of pure omega-3 fatty acids on diabetes and 















Figure 3.6. Comparison of retinal lipid profiles in fish oil 
supplemented diabetic Nile rats group with normal diet diabetic Nile 
rats group (■ Diabetic-ND; ■ Diabetic-Fish oil supplement) (P 




Figure 3.7. Comparison of glucose levels in fish oil supplemented 
Nile rats with normal diet group (■ Start of the experiment; ■ 


































(WT), we could not detect any VLC-PUFAs in the retinas of Akita mice. 
Akita mice do not produce insulin which leads to higher glucose levels and 
decreased adiponectin levels which in turn depletes the retinal VLC-PUFA levels and n-
3/n-6 LC-PUFA ratios. Even though the Akita mice had undetectable retinal VLC-PUFA 
levels, we could confirm that retinal LC-PUFA levels were decreased in the Akita mice in 
comparison to the WT mice. These results indicate that these mice had very depleted 
levels of lipids in the retina (Figure 3.8).  
 In the serum, we also observed significantly higher serum EPA/AA, n-3/n-6 LC-
PUFAs, and VLC-PUFA precursors ratios in EPA+DHA supplemented group in 
comparison to the control diet Akita group (Figure 3.9) (P<0.05). These results also 
indicate the important role that diet can play in diabetic dyslipidemia.  
 Serum adiponectin levels were significantly higher in the wild-type group when 
compared to the supplemented Akita mouse group (p<0.05). Higher serum adiponectin 
levels were lower in type-2 diabetes both in mice and humans (Figure 3.10). 
   
 
 
Figure 3.8. Comparison of retinal n-3/n-6 LC-PUFA levels in 
EPA+DHA supplement Akita mice group with control diet Akita 

















Figure 3.9. Comparison of serum lipid biomarkers in EPA+DHA 
supplement Akita mice group with control diet Akita group (■ WT- 




Figure 3.10. Comparison of Adiponectin levels in EPA+DHA 
supplemented Akita mice with normal diet group (■ WT-EPA+DHA; 





































 Even with the unique presence and specificity of VLC-PUFAs in the human 
retina, there are controversies regarding their beneficial effects and the clinical 
significance of their roles in health and disease. There is considerable evidence that 
mutations in the ELOVL4 gene, required for the biosynthesis of VLC-PUFAs in retina, 
result in Stargardt-3 (STGD3) disease, a dominant juvenile macular dystrophy (8, 13), 
but the mechanistic process by which STGD3 disease occurs, either by protein 
aggregation or by VLC-PUFA deficiency, is not well characterized (14, 15). Our clinical 
trials with STGD3 patients indicated that fish consumption (16) and possibly fish oil 
supplementation (17) improved the disease phenotype, which indicates that fish oil 
supplementation/ n-3 PUFAs supplementation can actually reverse VLC-PUFA 
deficiency and improve vision. Epidemiological studies generally support the 
recommendation that consumption of foods rich in n-3 LCPUFAs is associated with a 
lower risk of retinal degenerative diseases like AMD (5, 6), glaucoma (18), and diabetic 
retinopathy (19), but clinical intervention studies with n-3 PUFA supplements have been 
either negative or equivocal (20). 
 In the present study, lipid profiles of seven diabetic donor retinal punches were 
compared with 22 age-matched control donor retinal punches. This is the first report to 
measure VLC-PUFA levels in diabetic donor punches, and we observed a decreasing 
trend in VLC-PUFA levels and n-3/n-6 VLC-PUFA ratios in diabetic retinas in 
comparison to age-matched control retinas. However, since the number of eye tissues is 
20 
 
limited, we could not obtain any statistically significant difference. In correlation with our 
study, Kady et al. (21) reported that intravitreal delivery of human ELOVL4 reduced the 
diabetes-induced increase in vascular permeability, thereby increasing VLC-ceramides 
in diabetes. Tikhonenko et al. (22) also observed a decrease in retinal VLC-PUFAs 
levels and a  decrease in ELOVL4 expression levels as well as ELOVL4 protein levels in 
early diabetic animals in comparison to control animals. These studies indicate that 
diabetes has profound effects on VLC-PUFA levels even before detection of retinopathy 
symptom.  
Three of seven donors had diabetic retinopathy. Hence, we compared diabetes 
with no retinopathy (No DR) with diabetic retinopathy donors and also with age-matched 
controls. Even though the numbers were small, we observed in Figure 3.3 that VLC-
PUFA levels in diabetic retinopathy are lower than in the No DR group, indicating that 
diabetic retinopathy affects retinal VLC-PUFAs as well as membrane permeability. 
           In the present study, we also observed changes in serum LC-PUFAs and other 
lipid biomarkers. As shown in Figure 3.2, the fatty acids which elongate to give rise to n-
3 VLC-PUFAs are considered as n-3 VLC-PUFA precursors, and the same term is used 
for n-6 VLC-PUFA precursors. Compared to the age-matched control serum, diabetic 
serum has reduced ratios of DHA/AA and n-3/n-6 VLC-PUFA precursors. The ratio of n-
3/n-6 VLC-PUFA precursors indicates the presence of substrates for VLC-PUFAs in 
serum, and a significant reduction of this ratio indicates that there is not only a reduction 
in ELOVL4 expression levels in diabetes but also a decrease in n-3/n-6 VLC-PUFA 
precursors. AdipoR1, a receptor for adiponectin in the eye, known to control the 
infiltration of fatty acids to the retina is also known to be associated with retinal 
degeneration (9, 12) According to the present results, we did not observe any 
differences in AdipoR1 gene expression in these diabetic patients in relation to age-
matched controls. These results from the human retinal punches indicate that impaired 
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insulin metabolism causes dyslipidemia, which affects n-3/n-6 VLC-PUFA ratios and 
VLC-PUFA levels as well as other serum biomarkers in humans.  
        Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have long been studied for their 
therapeutic potential in the context of type 2 diabetes, insulin resistance, and glucose 
homeostasis. Crochemore et al. (23) and Ebbesson et al. (24) also demonstrated the 
influence of n-3 PUFA in type 2 diabetes women and Alaskan Eskimos and suggested 
that high dose of n-3 PUFAs in serum can reduce insulin sensitivity and glucose 
tolerance. Thorsdotter et al. (25) also correlated the amount of n-3 PUFA from cow’s 
milk to the prevalence of diabetes in Nordic populations.  In spite of all these population 
studies and mouse studies, there is a lack of concrete knowledge about the practical 
application of n-3 PUFA as nutritional therapeutics against insulin resistance in humans. 
Given the above studies, we hypothesize that supplementation with n-3 PUFAs/ fish oil 
to diabetic animal models improves glucose tolerance, n-3/n-6 LC-PUFA ratio in serum, 
and most importantly, counteracts the decreasing levels of VLC-PUFAs in the retina. 
Adiponectin is known to be the major regulator of lipid and glucose homeostasis through 
its insulin-sensitizing properties (26), and lower adiponectin contributes to vascular 
complications and diabetic retinopathy. Hence in this study, we also considered 
adiponectin as a biomarker for diabetes.  
      The Nile grass rat (Arvicanthis niloticus) is a diurnal rodent which is a becoming 
popular for studying circadian rhythms. It has a cone-rich retina with 30% cones in 
comparison to 3% cones in mice or rats (27), making it is a very useful model to study 
eye diseases, and it is also a good model to study metabolic syndromes and 
spontaneous diabetes (28). Diabetic Nile grass rats in the early phase of the disease 
develop hyperinsulinemia, and show a strong inverse correlation between plasma 
adiponectin and HbA1c levels (28). We hypothesized that Nile grass rats would be a 
good model to study diabetes and its effects on VLC-PUFAs. As discussed in the 
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methods section, we changed their regular guinea pig chow to an RMH 2000 diet, which 
altered their blood glucose levels and made all the male rats diabetic.  
           As discussed in Figure 3.4, the VLC-PUFA levels did not show any significant 
difference between the fish oil supplemented groups, and control diet groups, but the n-
3/n-6 VLC-PUFA ratio altered significantly. The retinal n-3/n-6 LC-PUFA ratio improved 
from 4.5 to 11 in the fish oil supplemented group, indicating decreased levels of 
dyslipidemia and improved n-3 VLC-PUFA precursor levels (Figure 3.6). To observe 
differences in retinal VLC-PUFA levels, we might have to supplement fish oil for longer 
periods than 4 weeks. We also observed that fish oil supplementation improved serum 
lipid biomarkers like EPA/AA, n-3/n-6 LC-PUFA ratios, and n-3/n-6 VLC-PUFA 
presursors (Figure 3.5), which shows the improvement in dyslipidemia in these animals. 
As shown in Figure 3.7, the glucose levels at the start of the experiment were 
approximately 250 mg/dL, which increased to above 600 mg/dL in the control animals 
during the course of the experiment, while supplementation with fish oil increased 
glucose levels to just 400 mg/dL, consistent with positive effects of 3% fish oil 
(containing 1360 mg/5 mL oil) supplementation on glucose tolerance. 
     Further, we have studied the effect of n-3 PUFAs in Akita mice which is an Ins2 
genetic diabetes (Ins2) mice model. Male heterozygous KO (Ins2-/+) develop 
hyperglycemia in less than 2 months, while homozygous KO die before birth. Akita mice 
show various retinal pathologies characteristic of early non-proliferative diabetic 
retinopathy (29) and also exhibit increased frequency of apoptic retinal neurons, 
increased vascular permeability (30), and decreased retinal blood flow (31). These 
properties could answer the question whether availability of substrate or lack of enzyme 
leads to loss of VLC-PUFAs in diabetes. After supplementation of 3-month-old Akita 
mice with EPA + DHA (2:1), we observed the serum LC-PUFAs and retinal LC-PUFA 
improved in comparision to control Akita mice. Unfortunately, no VLC-PUFAs were 
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detected in the eyes from both the supplemented and control Akita mice, as opposed to 
the wild-type supplemented mice. In spite of the lack of detectable VLC-PUFA levels, we 
observed that retinal n-3/n-6 LC-PUFAs improved significantly in supplemented Akita 
mice compared to control Akita mice (Figure 3.8). In correlation with our study, earlier 
studies suggested that n-3 PUFA supplementation effectively reduced pathological 
retinal neovascularization and protected retinal neurons and retinal ganglion cells in 
various animal models. Our results are consistent with a clinical study in India that lower 
n-3/n-6 ratio in dietary lipids increases the prevalence of type 2 diabetes and that higher 
n-3/n-6 ratios may restore normal insulin action (32). 
         Even though the VLC-PUFAs were undetectable, interestingly, we observed that n-
3 PUFAs supplementation in Akita mice improved the serum lipid profile. The n-3/n-6 
LC-PUFA, EPA/AA, and n-3/n-6 VLC-PUFA precursor ratios improved significantly in 
PUFA supplemented group compared to control Akita mice (Figure 3.9). Previous  
experiments have shown that adding n-3 LC-PUFAs to the diet reduces the progression 
of retinopathy compared with controls (33, 34). These animal studies found that a 2% 
change in dietary intake of n-3 LC-PUFA (n-3 vs n-6 FA) resulted in a 2-fold increase in 
retinal LC-PUFA, which is in correlation with our studies. Also, we observed that serum 
adiponectin improved in the n-3 PUFA supplemented group in comparison to the control 
group, indicating the beneficial effects of PUFA supplementation in diabetic mice. The 
serum adiponectin levels were in the order of WT<EPA+DHA<Control.  
          We need to further study the effects of supplementation using larger numbers of 
animals, and the period of supplementation should be more than 2 months to study the 
effects of retinal VLC-PUFA levels. Further studies with hispathologic observations and 
adiponectin levels will give us better knowledge of the benefits of fish oil 







1. Mathers CD, Loncar D. Projections of global mortality and burden of disease 
from 2002 to 2030. PLoS Medicine 2006;3(11):e442. doi: 
10.1371/journal.pmed.0030442. 
 
2. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic 
Epidemiology 2007;14(4):179-83. doi: 10.1080/09286580701396720. 
 
3. Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic 
retinopathy. Vision Research 2017;139:7-14. doi: 10.1016/j.visres.2017.04.003. 
 
4. Hammer SS, Busik JV. The role of dyslipidemia in diabetic retinopathy. Vision 
Research 2017;139:228-36. doi: 10.1016/j.visres.2017.04.010. 
 
5. SanGiovanni JP, Chew EY, Clemons TE, Davis MD, Ferris FL, 3rd, Gensler GR, 
Kurinij N, Lindblad AS, Milton RC, Seddon JM, et al. The relationship of dietary 
lipid intake and age-related macular degeneration in a case-control study: 
AREDS Report No. 20. Archives of Ophthalmology (Chicago, Ill : 1960) 
2007;125(5):671-9. doi: 10.1001/archopht.125.5.671. 
 
6. Tan JS, Wang JJ, Flood V, Mitchell P. Dietary fatty acids and the 10-year 
incidence of age-related macular degeneration: the Blue Mountains Eye Study. 
Archives of Ophthalmology (Chicago, Ill : 1960) 2009;127(5):656-65. doi: 
10.1001/archophthalmol.2009.76. 
 
7. Gorusupudi A, Liu A, Hageman GS, Bernstein PS. Associations of human retinal 
very long-chain polyunsaturated fatty acids with dietary lipid biomarkers. Journal 
of Lipid Research 2016;57(3):499-508. doi: 10.1194/jlr.P065540. 
 
8. Agbaga MP, Brush RS, Mandal MN, Henry K, Elliott MH, Anderson RE. Role of 
Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long 
chain fatty acids. Proceedings of the National Academy of Sciences of the United 
States of America 2008;105(35):12843-8. doi: 10.1073/pnas.0802607105. 
 
9. Rice DS, Calandria JM, Gordon WC, Jun B, Zhou Y, Gelfman CM, Li S, Jin M, 
Knott EJ, Chang B, et al. Adiponectin receptor 1 conserves docosahexaenoic 
acid and promotes photoreceptor cell survival. Nature Communications 
2015;6:6228. doi: 10.1038/ncomms7228. 
 
10. Liu A, Chang J, Lin Y, Shen Z, Bernstein PS. Long-chain and very long-chain 
polyunsaturated fatty acids in ocular aging and age-related macular 




11. Yi J, Li S, Jia X, Xiao X, Wang P, Guo X, Zhang Q. Evaluation of the ELOVL4, 
PRPH2 and ABCA4 genes in patients with Stargardt macular degeneration. 
Molecular Medicine Reports 2012;6(5):1045-9. doi: 10.3892/mmr.2012.1063. 
 
12. Kaarniranta K, Paananen J, Nevalainen T, Sorri I, Seitsonen S, Immonen I, 
Salminen A, Pulkkinen L, Uusitupa M. Adiponectin receptor 1 gene (ADIPOR1) 
variant is associated with advanced age-related macular degeneration in Finnish 
population. Neuroscience Letters 2012;513(2):233-7. doi: 
10.1016/j.neulet.2012.02.050. 
 
13. Vasireddy V, Wong P, Ayyagari R. Genetics and molecular pathology of 
Stargardt-like macular degeneration. Progress in Retinal and Eye Research 
2010;29(3):191-207. doi: 10.1016/j.preteyeres.2010.01.001. 
 
14. Logan S, Agbaga MP, Chan MD, Kabir N, Mandal NA, Brush RS, Anderson RE. 
Deciphering mutant ELOVL4 activity in autosomal-dominant Stargardt macular 
dystrophy. Proceedings of the National Academy of Sciences of the United 
States of America 2013;110(14):5446-51. doi: 10.1073/pnas.1217251110. 
 
15. Barabas P, Liu A, Xing W, Chen CK, Tong Z, Watt CB, Jones BW, Bernstein PS, 
Krizaj D. Role of ELOVL4 and very long-chain polyunsaturated fatty acids in 
mouse models of Stargardt type 3 retinal degeneration. Proceedings of the 
National Academy of Sciences of the United States of America 
2013;110(13):5181-6. doi: 10.1073/pnas.1214707110. 
 
16. Hubbard AF, Askew EW, Singh N, Leppert M, Bernstein PS. Association of 
adipose and red blood cell lipids with severity of dominant Stargardt macular 
dystrophy (STGD3) secondary to an ELOVL4 mutation. Archives of 
Ophthalmology (Chicago, Ill : 1960) 2006;124(2):257-63. doi: 
10.1001/archopht.124.2.257. 
 
17. Choi R, Gorusupudi A, Bernstein PS. Long-term follow-up of autosomal dominant 
Stargardt macular dystrophy (STGD3) subjects enrolled in a fish oil supplement 
interventional trial. Ophthalmic Genetics 2018:1-7. doi: 
10.1080/13816810.2018.1430240. 
 
18. Renard JP, Rouland JF, Bron A, Sellem E, Nordmann JP, Baudouin C, Denis P, 
Villain M, Chaine G, Colin J, et al. Nutritional, lifestyle and environmental factors 
in ocular hypertension and primary open-angle glaucoma: an exploratory case-
control study. Acta Ophthalmologica 2013;91(6):505-13. doi: 10.1111/j.1755-
3768.2011.02356.x. 
 
19. Sala-Vila A, Diaz-Lopez A, Valls-Pedret C, Cofan M, Garcia-Layana A, Lamuela-
Raventos RM, Castaner O, Zanon-Moreno V, Martinez-Gonzalez MA, Toledo E, 
et al. Dietary marine omega-3 fatty acids and incident sight-threatening 
retinopathy in middle-aged and older individuals with type 2 diabetes: prospective 
investigation from the PREDIMED trial. JAMA Ophthalmology 




20. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular 
degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized 
clinical trial. JAMA 2013;309(19):2005-15. doi: 10.1001/jama.2013.4997. 
 
21. Kady NM, Liu X, Lydic TA, Syed MH, Navitskaya S, Wang Q, Hammer SS, 
O'Reilly S, Huang C, Seregin SS, et al. ELOVL4-mediated production of very 
long chain ceramides stabilizes tight junctions and prevents diabetes-induced 
retinal vascular permeability. Diabetes 2018. doi: 10.2337/db17-1034. 
 
22. Tikhonenko M, Lydic TA, Wang Y, Chen W, Opreanu M, Sochacki A, McSorley 
KM, Renis RL, Kern T, Jump DB, et al. Remodeling of retinal Fatty acids in an 
animal model of diabetes: a decrease in long-chain polyunsaturated fatty acids is 
associated with a decrease in fatty acid elongases Elovl2 and Elovl4. Diabetes 
2010;59(1):219-27. doi: 10.2337/db09-0728. 
 
23. Crochemore IC, Souza AF, de Souza AC, Rosado EL. Omega-3 polyunsaturated 
fatty acid supplementation does not influence body composition, insulin 
resistance, and lipemia in women with type 2 diabetes and obesity. Nutrition in 
Clinical Practice : official publication of the American Society for Parenteral and 
Enteral Nutrition 2012;27(4):553-60. doi: 10.1177/0884533612444535. 
 
24. Ebbesson SO, Voruganti VS, Higgins PB, Fabsitz RR, Ebbesson LO, Laston S, 
Harris WS, Kennish J, Umans BD, Wang H, et al. Fatty acids linked to 
cardiovascular mortality are associated with risk factors. International Journal of 
Circumpolar Health 2015;74:28055. doi: 10.3402/ijch.v74.28055. 
 
25. Thorsdottir I, Hill J, Ramel A. Omega-3 fatty acid supply from milk associates 
with lower type 2 diabetes in men and coronary heart disease in women. 
Preventive Medicine 2004;39(3):630-4. doi: 10.1016/j.ypmed.2004.02.031. 
 
26. Frankenberg ADV, Reis AF, Gerchman F. Relationships between adiponectin 
levels, the metabolic syndrome, and type 2 diabetes: a literature review. Archives 
of Endocrinology and Metabolism 2017;61(6):614-22. doi: 10.1590/2359-
3997000000316. 
 
27. Gilmour GS, Gaillard F, Watson J, Kuny S, Mema SC, Bonfield S, Stell WK, 
Sauve Y. The electroretinogram (ERG) of a diurnal cone-rich laboratory rodent, 
the Nile grass rat (Arvicanthis niloticus). Vision Research 2008;48(27):2723-31. 
doi: 10.1016/j.visres.2008.09.004. 
 
28. Noda K, Melhorn MI, Zandi S, Frimmel S, Tayyari F, Hisatomi T, Almulki L, 
Pronczuk A, Hayes KC, Hafezi-Moghadam A. An animal model of spontaneous 
metabolic syndrome: Nile grass rat. FASEB Journal : official publication of the 
Federation of American Societies for Experimental Biology 2010;24(7):2443-53. 
doi: 10.1096/fj.09-152678. 
 
29. Han Z, Guo J, Conley SM, Naash MI. Retinal angiogenesis in the Ins2(Akita) 
mouse model of diabetic retinopathy. Investigative Ophthalmology & Visual 




30. Barber AJ, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW, 
Gardner TW, Bronson SK. The Ins2Akita mouse as a model of early retinal 
complications in diabetes. Investigative Ophthalmology & Visual Science 
2005;46(6):2210-8. doi: 10.1167/iovs.04-1340. 
 
31. Wright WS, Yadav AS, McElhatten RM, Harris NR. Retinal blood flow 
abnormalities following six months of hyperglycemia in the Ins2(Akita) mouse. 
Experimental Eye Research 2012;98:9-15. doi: 10.1016/j.exer.2012.03.003. 
 
32. Raheja BS, Sadikot SM, Phatak RB, Rao MB. Significance of the N-6/N-3 ratio 
for insulin action in diabetes. Annals of the New York Academy of Sciences 
1993;683:258-71. 
 
33. Sapieha P, Stahl A, Chen J, Seaward MR, Willett KL, Krah NM, Dennison RJ, 
Connor KM, Aderman CM, Liclican E, et al. 5-Lipoxygenase metabolite 4-HDHA 
is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. 
Science Translational Medicine 2011;3(69):69ra12. doi: 
10.1126/scitranslmed.3001571. 
 
34. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, Hong 
S, Pravda EA, Majchrzak S, Carper D, et al. Increased dietary intake of omega-3-
polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature 
Medicine 2007;13(7):868-73. doi: 10.1038/nm1591. 
 
